MEDI 8852

Drug Profile

MEDI 8852

Alternative Names: MEDI8852

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Humabs BioMed
  • Developer MedImmune
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Influenza A virus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Influenza A virus infections

Most Recent Events

  • 01 Dec 2016 MedImmune completes a phase I/II trial in Influenza-A virus infections (Monotherapy, Combination therapy) in USA and South Africa (IV) (NCT02603952)
  • 14 Oct 2016 Phase-II clinical trials in Influenza-A virus infections (Combination therapy) in Czech Republic, Germany (IV) (EudraCT2015-004276-29)
  • 14 Oct 2016 Phase-II clinical trials in Influenza-A virus infections (Combination therapy) in Latvia (IV) (EudraCT2015-004276-29) after October 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top